Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective

Sarah P. Blagden(Churchill Hospital), Louise Brown(North Manchester General Hospital), Jonathan Fennelly-Barnwell, F. Maignen(National Institute for Health and Care Excellence), Ly‐Mee Yu(Dartmouth–Hitchcock Medical Center), Pamela Kearns(National Institute for Health and Care Research), Alison M. Cooper(Association of the British Pharmaceutical Industry), Mark P. Lythgoe(Hammersmith Hospital), H Hughes(Cardiff and Vale University Health Board), Abeer M. Shaaban(Queen Elizabeth Hospital Birmingham), Stephanie Ellis(Greater London Authority), Sean Buckland(Pfizer (United Kingdom))
British Journal of Cancer
November 24, 2022
10.1038/s41416-022-02051-7
Cited by 2

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
|The Lancet Oncology|2020|351
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222